In the recent years, four cardiovascular outcome trials (CVOTs) have been conducted to assess the safety and efficacy of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on cardiovascular end-points in high risk type 2 diabetes patients (EMPA-REG OUTCOME, DECLARE-TIMI 58, CANVAS and VERTIS-CV) [1–4]. Here, SLC5A2 is linked to type 2 diabetes mellitus.